Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0130 • ACR Convergence 2024
Depression Genetic Risk, Diagnoses, and Treatments in Association with Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program
Jing Cui¹, Jeong Yee¹, Emily Oakes¹, Elizabeth Karlson¹, Leah Santacroce¹, Hongshu Guan¹, Laura D. Kubzansky², Karestan C. Koenen², Candace Feldman¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Diagnoses of depression, highly prevalent in SLE and RA populations, were associated with increased cardiovascular disease (CVD) risk in the All of Us Research…
Abstract Number: 0205 • ACR Convergence 2024
Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: A growing body of evidence highlights a link between rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE)…
Abstract Number: 0356 • ACR Convergence 2024
Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Hubert Marotte¹, Laure Gossec², Vered ABITBOL³, Eric SENBEL⁴, Guillaume BONNAUD⁵, Xavier ROBLIN⁶, Yoram BOUHNIK⁷, Stéphane NANCEY⁸, Nicolas MATHIEU⁹, jérôme FILIPPI¹⁰, Lucine VUITTON¹¹, Stéphane NAHON¹², Azeddine Dellal¹², Alice DENIS¹³, Caroline HABAUZIT¹³, Salim BENKHALIFA¹³ and Guillaume BOUGUEN¹⁴, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ²Sorbonne Université, Paris, France, ³Cochin University Hospital, Paris, France, ⁴Medical practice, Marseille, Marseille, France, ⁵Ambroise Paré Clinic, Toulouse, France, ⁶Saint-Etienne University Hospital, Saint-Etienne, France, ⁷Institut des MICI, Paris IBD Center, Neuilly-Sur-Seine, France, ⁸Hospices Civils de Lyon, Lyon, France, ⁹Clinic of Cèdres, Echirolles, France, ¹⁰Saint-Jean Clinic, Cagnes sur Mer, France, ¹¹Besançon university hospital, Besançon, France, ¹²Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, ¹³Celltrion Healthcare France, Issy Les Moulineaux, France, ¹⁴Rennes University Hospital, Rennes, France
Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…
Abstract Number: 0456 • ACR Convergence 2024
Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Yujie Su², Cassie Clinton³, David Curtis⁴, Laura Stradford⁵, Patrick Zueger⁶, William Benjamin Nowell⁷, Pankaj Patel⁸, Esteban Rivera⁹, Kelly Gavigan⁴, Shilpa Venkatachalam¹⁰ and Fenglong Xie³, ¹FASTER Medicine, Hoover, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶AbbVie Inc, North Chicago, IL, ⁷Regeneron, New York, NY, ⁸AbbVie Inc., North Chicago, IL, ⁹Global Healthy Living Foundation, Long Island City, NY, ¹⁰Global Healthy Living Foundation, New York, NY
Background/Purpose: Digital health technology to collect electronic patient reported outcomes (ePRO) and biosensor data are increasingly used to generate real-world data in pharmacoepidemiology. However, the…
Abstract Number: 0472 • ACR Convergence 2024
Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Bas Dijkshoorn¹, Sreen Mohamed², Romy Hansildaar², Henk Everaars³, Geoffrey Mooij³, Luuk Hopman³, Paul Knaapen³, Lourens Robbers³ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology center location Reade, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…
Abstract Number: 0489 • ACR Convergence 2024
Use of Chair Sit-to-Stand as a Pragmatic Alternative to Assess Frailty in Rheumatoid Arthritis
Hannah Brubeck¹, Kylie Riggles², Riley Bass³, Elizabeth Wahl⁴, James Andrews⁵, Namrata Singh⁶, ariela orkaby⁷, Joshua Baker⁸, Patti Katz⁹, Dolores Shoback¹⁰, Jose Garcia¹¹ and Katherine Wysham¹², ¹VA Puget Sound Health Care System, Seattle, WA, ²VA Puget Sound Health Care System, Bellevue, WA, ³VA Puget Sound Health Care System, Seattle, ⁴VA Puget Sound Healthcare System, Seattle, WA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Washington, Bellevue, WA, ⁷New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹UCSF, San Rafael, CA, ¹⁰San Francisco VA/University of California, San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System/University of Washington, Seattle, WA, ¹²VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty occurs earlier in people with rheumatoid arthritis (RA) than in the general population and is associated with poor health outcomes1, making it important…
Abstract Number: 0506 • ACR Convergence 2024
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
Takao Fujii¹, Nami Okamoto², Asami Abe³, Michiaki Takagi⁴, Nobunori Takahashi⁵, Atsuo Nakajima⁶, Ayako Nakajima⁷, Shingo Nakayamada⁸, Keiichiro Nishida⁹, Takeshi Kawaberi¹⁰, Naomi Sunaga¹⁰, Yuki Tsujita¹¹, Sumi Chonan¹², Masataka Kuwana¹³ and Yoshiya Tanaka¹⁴, ¹Wakayama Medical University, Wakayama, Japan, ²Osaka Rosai Hospital, Sakai-city, Osaka, Japan, ³Niigata Rheumatic Center, Shibata, Japan, ⁴Yamagata University Faculty of Medicine, Yamagata, Japan, ⁵Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶Ueno Dialysis Clinic, Tokyo, Japan, ⁷Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, ⁹Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ¹⁰Abbvie GK, Minato-Ku, Tokyo, Japan, ¹¹AbbVie, Minato City Tokyo, Japan, ¹²Abbvie GK, Tokyo, Japan, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 0771 • ACR Convergence 2024
Arid5b Controls Pathologic Inflammatory versus Invasive Fibroblast Behavior
Angela Zou¹, Suppawat Kongthong², Cassandra Murphy², Gerald Watts³, Alisa Mueller⁴ and Michael Brenner⁵, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Brookline, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts assume both inflammatory and tissue invasive roles in rheumatoid arthritis (RA). Recent studies have shown that these inflammatory and invasive functions are…
Abstract Number: 0872 • ACR Convergence 2024
Investigating the Natural Improvement of Rheumatoid Arthritis During Pregnancy
Matthew Wright¹, Dana Goin², Mette Kiel Smed³, Nicholas Jewell⁴, J Lee Nelson⁵, Merete Hetland⁶ and Damini Jawaheer⁷, ¹Children's Hospital Oakland Research Institute/Northwestern University, Chicago, ²UCSF, San Francisco, CA, ³Juliane Marie Centret, Copenhagen, Denmark, ⁴UC Berkeley, Berkeley, CA, ⁵University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, ⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁷Children's Hospital Oakland Research Institute/Northwestern University, Chicago, IL
Background/Purpose: Pregnancy can induce a natural improvement of rheumatoid arthritis (RA) in 50-75% of women with the disease, while others may worsen or remain unchanged.…
Abstract Number: 0938 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis
Agnieszka Lastowska¹, Anders Nguyen², Miriam Bollmann² and Mattias Svensson³, ¹University of Gothenburg, Goteborg, Sweden, ²University of Gothenburg, Göteborg, Sweden, ³University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid Cells (ILCs) are the innate counterparts to T cells and can be divided into three functionally distinct subpopulations: Group 1 (ILC1), Group…
Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
Abstract Number: 1042 • ACR Convergence 2024
Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
Racheal Githumbi¹, Steven Katz², Ania Kania-Richmond¹, Kim Giroux³, Yvonne Wallace³, Cheryl Barnabe¹, Glen Hazlewood¹, C. Allyson Jones², Amanda Steiman⁴, Anshula Ambasta¹, Diane Lacaille⁵, Elaine Yacyshyn², Jessica Widdifield⁶, Natasha Gakhal⁷, Tyler Williamson¹ and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Patient Partner, Calgary, AB, Canada, ⁴Sinai Health System, Toronto, ON, Canada, ⁵Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁶Sunnybrook Research Institute / ICES / UofT Institute of Health Policy, Management & Evaluation, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcome measures (PROMs) are essential tools for prioritizing patient-centric care and enhancing health system-performance measurement in rheumatology. Effective use of PROMs collected in…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 1338 • ACR Convergence 2024
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Mark Tatangelo³ and Claire Bombardier³, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].